Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Schizophrenia

  Free Subscription


Articles published in Neuropsychopharmacology

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    August 2019
  1. HO NF, Holt DJ, Cheung M, Iglesias JE, et al
    Correction: Progressive decline in hippocampal CA1 volume in individuals at ultra-high-risk for psychosis who do not remit: findings from the longitudinal youth at risk study.
    Neuropsychopharmacology. 2019 Aug 14. pii: 10.1038/s41386-019-0477.
    PubMed     Text format     Abstract available


    July 2019
  2. HOMAN P, Argyelan M, Fales CL, Barber AD, et al
    Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis.
    Neuropsychopharmacology. 2019 Jul 17. pii: 10.1038/s41386-019-0464.
    PubMed     Text format     Abstract available


  3. KARCHER NR, Hua JPY, Kerns JG
    Striatum-related functional activation during reward- versus punishment-based learning in psychosis risk.
    Neuropsychopharmacology. 2019 Jul 4. pii: 10.1038/s41386-019-0455.
    PubMed     Text format     Abstract available


    June 2019
  4. LEUCHT S, Chaimani A, Mavridis D, Leucht C, et al
    Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis.
    Neuropsychopharmacology. 2019 Jun 18. pii: 10.1038/s41386-019-0440.
    PubMed     Text format     Abstract available


  5. HUANG AS, Rogers BP, Anticevic A, Blackford JU, et al
    Brain function during stages of working memory in schizophrenia and psychotic bipolar disorder.
    Neuropsychopharmacology. 2019 Jun 11. pii: 10.1038/s41386-019-0434.
    PubMed     Text format     Abstract available


  6. YAO L, Li F, Liu J, Liao W, et al
    Functional brain networks in never-treated and treated long-term Ill schizophrenia patients.
    Neuropsychopharmacology. 2019 Jun 4. pii: 10.1038/s41386-019-0428.
    PubMed     Text format     Abstract available


  7. KRAGULJAC NV, Anthony T, Monroe WS, Skidmore FM, et al
    A longitudinal neurite and free water imaging study in patients with a schizophrenia spectrum disorder.
    Neuropsychopharmacology. 2019 Jun 1. pii: 10.1038/s41386-019-0427.
    PubMed     Text format     Abstract available


    May 2019
  8. QUARMLEY M, Gur RC, Turetsky BI, Watters AJ, et al
    Reduced safety processing during aversive social conditioning in psychosis and clinical risk.
    Neuropsychopharmacology. 2019 May 21. pii: 10.1038/s41386-019-0421.
    PubMed     Text format     Abstract available


  9. DE COSTER L, Lin L, Mathalon DH, Woolley JD, et al
    Neural and behavioral effects of oxytocin administration during theory of mind in schizophrenia and controls: a randomized control trial.
    Neuropsychopharmacology. 2019 May 18. pii: 10.1038/s41386-019-0417.
    PubMed     Text format     Abstract available


  10. RAMMOS A, Gonzalez LAN, Weinberger DR, Mitchell KJ, et al
    The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia.
    Neuropsychopharmacology. 2019 May 11. pii: 10.1038/s41386-019-0410.
    PubMed     Text format     Abstract available


  11. JACOBS GR, Ameis SH, Lisa Ji J, Viviano JD, et al
    Developmentally divergent sexual dimorphism in the cortico-striatal-thalamic-cortical psychosis risk pathway.
    Neuropsychopharmacology. 2019 May 6. pii: 10.1038/s41386-019-0408.
    PubMed     Text format     Abstract available


    April 2019
  12. TAPIAS-ESPINOSA C, Rio-Alamos C, Sanchez-Gonzalez A, Oliveras I, et al
    Schizophrenia-like reduced sensorimotor gating in intact inbred and outbred rats is associated with decreased medial prefrontal cortex activity and volume.
    Neuropsychopharmacology. 2019 Apr 16. pii: 10.1038/s41386-019-0392.
    PubMed     Text format     Abstract available


    March 2019
  13. LEUCHT S, Barabassy A, Laszlovszky I, Szatmari B, et al
    Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Neuropsychopharmacology. 2019 Mar 5. pii: 10.1038/s41386-019-0363.
    PubMed     Text format     Abstract available


  14. BITTER I, Lieberman JA, Gaudoux F, Sokoloff P, et al
    Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.
    Neuropsychopharmacology. 2019 Mar 1. pii: 10.1038/s41386-019-0355.
    PubMed     Text format     Abstract available


    February 2019
  15. KRUIPER C, Glenthoj BY, Oranje B
    Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.
    Neuropsychopharmacology. 2019 Feb 23. pii: 10.1038/s41386-019-0351.
    PubMed     Text format     Abstract available


  16. MCKINNEY BC, MacDonald ML, Newman JT, Shelton MA, et al
    Density of small dendritic spines and microtubule-associated-protein-2 immunoreactivity in the primary auditory cortex of subjects with schizophrenia.
    Neuropsychopharmacology. 2019 Feb 22. pii: 10.1038/s41386-019-0350.
    PubMed     Text format     Abstract available


  17. MAHMOUDI E, Fitzsimmons C, Geaghan M, Shannon Weickert C, et al
    Circular RNA biogenesis is decreased in postmortem cortical gray matter in schizophrenia and may alter the bioavailability of associated miRNA.
    Neuropsychopharmacology. 2019 Feb 20. pii: 10.1038/s41386-019-0348.
    PubMed     Text format     Abstract available


  18. STJEPAN C, Gregor L, Stephanie T, Christina A, et al
    Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.
    Neuropsychopharmacology. 2019 Feb 6. pii: 10.1038/s41386-019-0328.
    PubMed     Text format     Abstract available


    January 2019
  19. HOMAN P, Argyelan M, DeRosse P, Szeszko P, et al
    Structural similarity networks predict clinical outcome in early-phase psychosis.
    Neuropsychopharmacology. 2019 Jan 24. pii: 10.1038/s41386-019-0322.
    PubMed     Text format     Abstract available


  20. DAVIES C, Paloyelis Y, Rutigliano G, Cappucciati M, et al
    Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.
    Neuropsychopharmacology. 2019 Jan 9. pii: 10.1038/s41386-018-0311.
    PubMed     Text format     Abstract available


  21. WYNN JK, Green MF, Hellemann G, Reavis EA, et al
    A dose-finding study of oxytocin using neurophysiological measures of social processing.
    Neuropsychopharmacology. 2019;44:289-294.
    PubMed     Text format     Abstract available


    December 2018
  22. BRUCATO G, Appelbaum PS, Masucci MD, Rolin S, et al
    Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness.
    Neuropsychopharmacology. 2018 Dec 27. pii: 10.1038/s41386-018-0304.
    PubMed     Text format     Abstract available


  23. SHAHAB S, Mulsant BH, Levesque ML, Calarco N, et al
    Brain structure, cognition, and brain age in schizophrenia, bipolar disorder, and healthy controls.
    Neuropsychopharmacology. 2018 Dec 20. pii: 10.1038/s41386-018-0298.
    PubMed     Text format     Abstract available


    November 2018
  24. TAKEUCHI H, Siu C, Remington G, Fervaha G, et al
    Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
    Neuropsychopharmacology. 2018 Nov 22. pii: 10.1038/s41386-018-0278.
    PubMed     Text format     Abstract available


    October 2018
  25. HOCHBERGER WC, Joshi YB, Thomas ML, Zhang W, et al
    Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.
    Neuropsychopharmacology. 2018 Oct 30. pii: 10.1038/s41386-018-0256.
    PubMed     Text format     Abstract available


  26. VANOVER KE, Davis RE, Zhou Y, Ye W, et al
    Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.
    Neuropsychopharmacology. 2018 Oct 26. pii: 10.1038/s41386-018-0251.
    PubMed     Text format     Abstract available


  27. SCHWEIGER JI, Bilek E, Schafer A, Braun U, et al
    Effects of BDNF Val(66)Met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans.
    Neuropsychopharmacology. 2018 Oct 25. pii: 10.1038/s41386-018-0248.
    PubMed     Text format     Abstract available


  28. LEGIND CS, Broberg BV, Mandl RCW, Brouwer R, et al
    Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a (1)[H]-spectroscopy twin study.
    Neuropsychopharmacology. 2018 Oct 9. pii: 10.1038/s41386-018-0236.
    PubMed     Text format     Abstract available


  29. GONCALVES VF, Cuperfain AB, Kennedy JL
    Sex differences in schizophrenia: estrogen and mitochondria.
    Neuropsychopharmacology. 2018 Oct 7. pii: 10.1038/s41386-018-0228.
    PubMed     Text format    


  30. MODINOS G, Simsek F, Azis M, Bossong M, et al
    Correction: Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology. 2018 Oct 2. pii: 10.1038/s41386-018-0118.
    PubMed     Text format     Abstract available


    September 2018
  31. SONNENSCHEIN SF, Gill KM, Grace AA
    State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.
    Neuropsychopharmacology. 2018 Sep 18. pii: 10.1038/s41386-018-0219.
    PubMed     Text format     Abstract available


  32. BOGART LJ, O'Donnell P
    Multiple long-range inputs evoke NMDA currents in prefrontal cortex fast-spiking interneurons.
    Neuropsychopharmacology. 2018;43:2101-2108.
    PubMed     Text format     Abstract available


    August 2018
  33. CHUNG DW, Chung Y, Bazmi HH, Lewis DA, et al
    Altered ErbB4 splicing and cortical parvalbumin interneuron dysfunction in schizophrenia and mood disorders.
    Neuropsychopharmacology. 2018 Aug 2. pii: 10.1038/s41386-018-0169.
    PubMed     Text format     Abstract available


    July 2018
  34. SHAKORY S, Watts JJ, Hafizi S, Da Silva T, et al
    Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.
    Neuropsychopharmacology. 2018 Jul 28. pii: 10.1038/s41386-018-0163.
    PubMed     Text format     Abstract available


  35. FAAY MDM, Czobor P, Sommer IEC
    Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis.
    Neuropsychopharmacology. 2018 Jul 23. pii: 10.1038/s41386-018-0161.
    PubMed     Text format     Abstract available


  36. RAJAGOPAL L, Huang M, Michael E, Kwon S, et al
    TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia.
    Neuropsychopharmacology. 2018 Jul 23. pii: 10.1038/s41386-018-0160.
    PubMed     Text format     Abstract available


    June 2018
  37. ULIANA DL, Resstel LBM, Grace AA
    Fear extinction disruption in a developmental rodent model of schizophrenia correlates with an impairment in basolateral amygdala-medial prefrontal cortex plasticity.
    Neuropsychopharmacology. 2018 Jun 23. pii: 10.1038/s41386-018-0128.
    PubMed     Text format     Abstract available


    May 2018
  38. HOLPER L, Ben-Shachar D, Mann JJ
    Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.
    Neuropsychopharmacology. 2018 May 16. pii: 10.1038/s41386-018-0090.
    PubMed     Text format     Abstract available


  39. NOUR MM, McCutcheon R, Howes OD
    The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis.
    Neuropsychopharmacology. 2018;43:1195-1196.
    PubMed     Text format    


    April 2018
  40. NEVES GA, Grace AA
    alpha7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia.
    Neuropsychopharmacology. 2018 Apr 19. pii: 10.1038/s41386-018-0066.
    PubMed     Text format     Abstract available


  41. CHIAPPELLI J, Rowland LM, Notarangelo FM, Wijtenburg SA, et al
    Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 18. pii: 10.1038/s41386-018-0072.
    PubMed     Text format     Abstract available


  42. HAFIZI S, Da Silva T, Meyer JH, Kiang M, et al
    Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study.
    Neuropsychopharmacology. 2018 Apr 13. pii: 10.1038/s41386-018-0061.
    PubMed     Text format     Abstract available


  43. AVRAM M, Brandl F, Bauml J, Sorg C, et al
    Cortico-thalamic hypo- and hyperconnectivity extend consistently to basal ganglia in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 12. pii: 10.1038/s41386-018-0059.
    PubMed     Text format     Abstract available


  44. ERMAKOVA AO, Knolle F, Justicia A, Bullmore ET, et al
    Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis.
    Neuropsychopharmacology. 2018 Apr 5. pii: 10.1038/s41386-018-0056.
    PubMed     Text format     Abstract available


  45. KESHAVAN MS
    Larry J Seidman.
    Neuropsychopharmacology. 2018;43:1189-1190.
    PubMed     Text format    


    March 2018
  46. DOGAN AE, Yuksel C, Du F, Chouinard VA, et al
    Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.
    Neuropsychopharmacology. 2018 Mar 14. pii: 10.1038/s41386-018-0041.
    PubMed     Text format     Abstract available


    February 2018
  47. CHIAPPELLI J, Notarangelo FM, Pocivavsek A, Thomas MAR, et al
    Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 27. pii: 10.1038/s41386-018-0038.
    PubMed     Text format     Abstract available


  48. O'DONOVAN SM, Sullivan C, Koene R, Devine E, et al
    Cell-subtype-specific changes in adenosine pathways in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 26. pii: 10.1038/s41386-018-0028.
    PubMed     Text format     Abstract available


  49. BARNETT I, Torous J, Staples P, Sandoval L, et al
    Relapse prediction in schizophrenia through digital phenotyping: a pilot study.
    Neuropsychopharmacology. 2018 Feb 22. pii: 10.1038/s41386-018-0030.
    PubMed     Text format     Abstract available


  50. BERNSTEIN HG, Dobrowolny H, Keilhoff G, Bogerts B, et al
    Reduced Density of DISC1 Expressing Astrocytes in the Dentate Gyrus but not in the Subventricular Zone in Schizophrenia.
    Neuropsychopharmacology. 2018;43:457-458.
    PubMed     Text format    


  51. ALLSWEDE DM, Zheutlin AB, Chung Y, Anderson K, et al
    Complement Gene Expression Correlates with Superior Frontal Cortical Thickness in Humans.
    Neuropsychopharmacology. 2018;43:525-533.
    PubMed     Text format     Abstract available


    January 2018
  52. MODINOS G, Simsek F, Azis M, Bossong M, et al
    Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology. 2018 Jan 30. pii: 10.1038/s41386-017-0004.
    PubMed     Text format     Abstract available


  53. YOUNG JW, Light GA
    Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap.
    Neuropsychopharmacology. 2018;43:230-231.
    PubMed     Text format    


    December 2017
  54. DOYLE GA, Berrettini WH
    Failure to Replicate an Association of a LINE-1 Element in ERI1 Exoribonuclease Family Member 3 (ERI3) with Schizophrenia.
    Neuropsychopharmacology. 2017;42:2471.
    PubMed     Text format    


    November 2017
  55. PERKINS KA, Chengappa KR, Karelitz JL, Boldry MC, et al
    Initial Cross-Over Test of a Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers with or Without Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 29. pii: npp2017292. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  56. SWERDLOW NR, Bhakta SG, Talledo JA, Franz DM, et al
    Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.
    Neuropsychopharmacology. 2017 Nov 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  57. NAGELS A, Cabanis M, Oppel A, Kirner-Veselinovic A, et al
    S-Ketamine-Induced NMDA Receptor Blockade During Natural Speech Production and its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  58. STEFANIK L, Erdman L, Ameis SH, Foussias G, et al
    Brain-Behavior Participant Similarity Networks Among Youth and Emerging Adults with Schizophrenia Spectrum, Autism Spectrum, or Bipolar Disorder and Matched Controls.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  59. GIRGIS RR, Ciarleglio A, Choo T, Haynes G, et al
    A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, an Interleukin-6 Receptor Antibody, for Residual Symptoms in Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 1. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    September 2017
  60. SMUCNY J, Lesh TA, Newton K, Niendam T, et al
    Levels of Cognitive Control: A Functional Magnetic Resonance Imaging-Based Test of an RDoC Domain Across Bipolar Disorder and Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  61. RAMSAY IS, Fryer S, Boos A, Roach BJ, et al
    Response to Targeted Cognitive Training Correlates with Change in Thalamic Volume in a Randomized Trial for Early Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    August 2017
  62. KEM WR, Olincy A, Johnson L, Harris J, et al
    Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation.
    Neuropsychopharmacology. 2017 Aug 21. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  63. O'DONNELL P
    Microglia Activation in Subjects at Risk for Psychosis, Fact or Fiction?
    Neuropsychopharmacology. 2017 Aug 18. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  64. LEE M, Balla A, Sershen H, Sehatpour P, et al
    Rodent Mismatch Negativity (MMN)/Theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Neuropsychopharmacology. 2017 Aug 17. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    July 2017
  65. BRUCATO G, Appelbaum PS, Lieberman JA, Wall MM, et al
    A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort.
    Neuropsychopharmacology. 2017 Jul 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    June 2017
  66. COSGROVE D, Mothersill O, Kendall K, Konte B, et al
    Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory.
    Neuropsychopharmacology. 2017 Jun 13. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  67. HAFIZI S, Da Silva T, Gerritsen C, Kiang M, et al
    Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: An In-Vivo PET Study with [18F]FEPPA.
    Neuropsychopharmacology. 2017 Jun 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  68. DOYLE GA, Crist RC, Karatas ET, Hammond MJ, et al
    Analysis of LINE-1 Elements in DNA from Postmortem Brains of Individuals with Schizophrenia.
    Neuropsychopharmacology. 2017 Jun 6. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    April 2017
  69. RABIN RA, Barr MS, Goodman MS, Herman Y, et al
    Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia versus Non-Psychiatric Controls.
    Neuropsychopharmacology. 2017 Apr 26. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  70. LIGHT GA, Zhang W, Joshi YB, Bhakta S, et al
    Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Neuropsychopharmacology. 2017 Apr 20. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  71. EISENBERG DP, Yankowitz L, Ianni AM, Rubinstein DY, et al
    Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.
    Neuropsychopharmacology. 2017 Apr 7. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: